Breast Cancer Trial, Not Yet Recruiting
voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice
Who may and may not be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who may be able to join
- Adults aged 18 or older, of any gender.
- People with a confirmed diagnosis of HER2-positive advanced breast cancer (based on laboratory testing of tumour tissue or cells), with known hormone receptor status.
- People whose cancer cannot be removed by surgery and has either spread to other parts of the body, or has come back after earlier treatment — if it has come back, at least 6 months must have passed since the person last received the targeted drugs trastuzumab or pertuzumab in that earlier treatment setting.
- People who have already completed 4 to 8 cycles of an initial treatment phase using only trastuzumab, pertuzumab, and a taxane (a type of chemotherapy) as the first treatment for advanced breast cancer, and whose cancer has not progressed since finishing that phase.
- People whose brain scan results at screening show either no brain metastases (cancer spread to the brain), or untreated brain metastases that are not causing symptoms and do not require immediate local treatment, and that have not grown since starting the initial treatment phase (confirm with trial site).
- People with a general health and activity level rated 0, 1, or 2 on a standard medical scale (where 0 means fully active and 2 means able to care for oneself but unable to do work activities).
- People who are planned to receive a maintenance treatment combination including pyrotinib together with trastuzumab and pertuzumab.
- Women who could become pregnant must have a negative pregnancy blood test before starting the trial and must use a highly effective method of contraception from the start of the study until at least 6 months after the last dose of study treatment.
- People who are willing to take part and have provided written consent before any trial-related procedures begin.
Who may not be able to join
Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.
- People who have been diagnosed with another type of cancer within the past 5 years.
- People who have previously been treated with any HER2- or EGFR-targeting tyrosine kinase inhibitor drug, including pyrotinib, lapatinib, tucatinib, neratinib, or afatinib.
- People who are unlikely or unable to attend follow-up visits as required by the trial.
- People who the trial doctor considers unsuitable for participation for any other reason.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: 010-8819 6406
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Primary endpoints
Progression-free survival (PFS)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.